- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05836987
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation (REACT-AF)
REACT-AF: Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
REACT-AF is a prospective, unblinded, randomized (1:1 allocation), multi-center, investigational clinical trial of men and women aged 22-85 with a documented history of symptomatic or asymptomatic paroxysmal or persistent (AF) and a moderate risk of stroke measured by CHA2DS2-VASc score 1-4 (which stands for Congestive heart failure, Hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled), Vascular disease, age 65 to 74 and sex category (female)). Participants randomized to the experimental arm (on demand DOAC) will take the participants DOAC for 30 consecutive days following a qualifying AF episode (i.e., greater than1 hour) detected by the AFSW. Participants randomized to the standard of care (control) arm will remain on previously prescribed continuous DOAC throughout the study.
A total of 5350 participants will be enrolled across up to 100 study sites targeting two-thirds academic and one-third private practices, with academic practices also enrolling from affiliated community sites. The investigators anticipate evaluating 7643 consented individuals with external monitoring to ensure that a low AF burden population will be randomized. Up to 200 participants may be enrolled at any one site, and participation will last up to 60 months.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Nicole Odenwald
- Phone Number: 650-725-3187
- Email: nicoleod@stanford.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- Not yet recruiting
- University of Southern California - Keck School of Medicine
-
Principal Investigator:
- Junaid Zaman, MD
-
Contact:
- Preetha Ramanarayan
- Phone Number: 805-807-7206
- Email: preetha.ramanaranyan@med.usc.edu
-
Contact:
- Stephanie Chao
- Phone Number: (323) 442-0750
- Email: Stephanie.Chao@med.usc.edu
-
Los Angeles, California, United States, 90095
- Recruiting
- University of California Los Angeles (UCLA Health)
-
Contact:
- Zackary Ortega
- Email: zmortega@mednet.ucla.edu
-
Contact:
- Monserrath Campos
- Email: monserrathcampos@mednet.ucla.edu
-
Principal Investigator:
- David Cho, MD
-
Sacramento, California, United States, 95817
- Recruiting
- UC Davis Health
-
Contact:
- Maryfel Llanillo
- Email: mlparaiso@ucdavis.edu
-
Principal Investigator:
- Uma Srivatsa
-
San Diego, California, United States, 92103
- Recruiting
- Scripps Health
-
Principal Investigator:
- Evan Muse
-
Contact:
- Carolina Robertson
- Email: Robertson.Carolina@scrippshealth.org
-
Contact:
- Janet Lawrence
- Email: Lawrence.Janet@scrippshealth.org
-
Stanford, California, United States, 94305
- Recruiting
- Stanford University
-
Contact:
- Alyssa Hernandez
- Phone Number: 650-498-7032
- Email: alyssahernandez@stanford.edu
-
Principal Investigator:
- Alexander Perino
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado
-
Contact:
- Megan Collett
- Phone Number: 970-624-1581
- Email: megan.collett@uchealth.org
-
Contact:
- Tiffany Herrera
- Email: tiffany.herrera@uchealth.org
-
Principal Investigator:
- Amar Trivedi
-
Littleton, Colorado, United States, 80120
- Recruiting
- South Denver Cardiology Associates, P.C.
-
Contact:
- Mary Soltau
- Phone Number: 303-703-2191
- Email: msoltau@southdenver.com
-
Principal Investigator:
- Srikanth Sundaram
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20032
- Recruiting
- St. Elizabeth's Medical Center
-
Contact:
- Rina Vaquerano
- Phone Number: 617-789-2023
- Email: rina.vaquerano@steward.org
-
Principal Investigator:
- John Wylie
-
Washington, District of Columbia, United States, 20037
- Recruiting
- Medical Faculty Associates George Washington University
-
Contact:
- Alfateh Sidahmed
- Phone Number: 202-741-2353
- Email: asidahmed@mfa.gwu.edu
-
Contact:
- Catherine Cantlay
- Phone Number: (202) 741-2559
- Email: ccantlay@mfa.gwu.edu
-
Principal Investigator:
- Allen Solomon
-
-
Florida
-
Clearwater, Florida, United States, 33759
- Recruiting
- Baycare Health systems
-
Contact:
- Karen Herring
- Phone Number: 280209 813-875-9000
- Email: karen.herring@baycare.org
-
Principal Investigator:
- Kevin Makati
-
Gainesville, Florida, United States, 32611
- Recruiting
- University of Florida
-
Contact:
- Sarah Long
- Email: Sarah.Long@medicine.ufl.edu
-
Contact:
- Janette Bostick
- Phone Number: (352) 273-8933
- Email: Janette.Bostick@medicine.ufl.edu
-
Principal Investigator:
- Mohammed Ruzieh, MD
-
Jacksonville, Florida, United States, 32224
- Not yet recruiting
- Mayo Clinic
-
Contact:
- Federico Rey Simon
- Phone Number: 904-953-2000
- Email: Simon.FedericoRey@mayo.edu
-
Principal Investigator:
- Andrew Tseng, MD
-
Sarasota, Florida, United States, 34236
- Recruiting
- Sarasota Memorial Health Care System
-
Contact:
- Alexandra Gardner
- Phone Number: 941-917-5916
- Email: Alexandra-Gardner@smh.com
-
Principal Investigator:
- Smirti Banthia, MD
-
-
Georgia
-
Atlanta, Georgia, United States, 30332
- Recruiting
- Emory University
-
Contact:
- Thomas Preiser
- Email: tpreise@emory.edu
-
Contact:
- Jovita Brevard
- Phone Number: jovita.johnson@emory.edu
-
Principal Investigator:
- Michael Lloyd
-
Warner Robins, Georgia, United States, 31093
- Recruiting
- Georgia Arrhythmia Consultants and Research Institute
-
Contact:
- Simisola Oludare
- Phone Number: 478-703-0402
- Email: soludare@gacri.com
-
Principal Investigator:
- Feliz Sogade, MD
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Recruiting
- Rush University Medical Center
-
Contact:
- Nusrat Jahan
- Phone Number: 312-942-1630
- Email: nusrat_jahan@rush.edu
-
Contact:
- Mary Ann Donahue
- Phone Number: (312) 942-1309
- Email: mary_a_donahue@rush.edu
-
Principal Investigator:
- Annabelle Volgman, MD
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago
-
Contact:
- Shahram Sarrafi
- Email: ssarrafi1@uchicagomedicine.org
-
Principal Investigator:
- Cevher Ozcan, MD
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Principal Investigator:
- Bradley Knight
-
Contact:
- BCVI Clinical Trials Unit
- Email: heartresearch@northwestern.edu
-
Chicago, Illinois, United States, 60660
- Recruiting
- Loyola University Chicago
-
Contact:
- Nancy Schoenecker
- Phone Number: 708-216-2646
- Email: nschoenecker@luc.edu
-
Contact:
- Jean Del Priore
- Phone Number: (708) 216-2644
- Email: jdelpri@luc.edu
-
Principal Investigator:
- Peter Santucci, MD
-
Chicago, Illinois, United States, 60607
- Recruiting
- University of Illinois Chicago
-
Contact:
- Jood Dabbas
- Phone Number: (312) 355-0700
- Email: jdabbas@uic.edu
-
Principal Investigator:
- Dana Johnson
-
Contact:
- Muriel Chen
- Email: yining@uic.edu
-
Elk Grove Village, Illinois, United States, 60007
- Recruiting
- Alexian Brothers Health System
-
Principal Investigator:
- Taral Patel, MD
-
Contact:
- Dina Yassan
- Email: dina.yassen@ascension.org
-
Contact:
- Elizabeth Hejna
- Phone Number: 716-888-4736
- Email: ehejna@buffalo.edu
-
Evanston, Illinois, United States, 60201
- Not yet recruiting
- NorthShore University HealthSystem
-
Contact:
- Marisa Durante
- Phone Number: 847-570-2125
- Email: mdurante@northshore.org
-
Principal Investigator:
- Jeremiah Wasserlauf, MD
-
Naperville, Illinois, United States, 60540
- Recruiting
- Midwest Cardiovascular Institute
-
Contact:
- Josilyn Klimek
- Email: Josilyn.Klimek@cardio.com
-
Principal Investigator:
- Moeen Saleem
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Recruiting
- Ascension St. Vincent
-
Contact:
- Regina Margiotti
- Phone Number: 317-583-6151
- Email: regina.margiotti@ascension.org
-
Contact:
- Ann Renick
- Phone Number: (317) 338-6152
- Email: anne.renick@ascension.org
-
Principal Investigator:
- Eric Prystowsky
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa Hospitals and Clinics
-
Contact:
- Trisha Elliott
- Phone Number: 319-384-1628
- Email: trisha-elliott@uiowa.edu
-
Principal Investigator:
- Samuel Johnston
-
-
Maine
-
Scarborough, Maine, United States, 04074
- Recruiting
- Maine Medical Partners MaineHealth Cardiology
-
Principal Investigator:
- Jordan Leyton-Mange, MD
-
Contact:
- Hilary Curtis
- Phone Number: 207-303-1571
- Email: hilary.curtis@mainehealth.org
-
Contact:
- Brenda Galsgow
- Phone Number: (207) 303-1304
- Email: brenda.glasgow@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, United States, 21218
- Recruiting
- Johns Hopkins Univeristy
-
Contact:
- Michele Martucci
- Phone Number: 410-502-0517
- Email: mmill148@jhmi.edu
-
Principal Investigator:
- Hugh Calkins
-
Contact:
- Natalie Horstman
- Email: nhorstm3@jhu.edu
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Brigham and Women's Hospital
-
Contact:
- Carlos Matostirado
- Email: cmatostirado@bwh.harvard.edu
-
Contact:
- Carlos Patino Rivas
- Email: cpatinorivas@bwh.harvard.edu
-
Principal Investigator:
- Paul Zei, MD
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Beth Israel Deaconess Medical Center
-
Contact:
- Jenifer M Kaufman
- Phone Number: 617-632-8956
- Email: jmkaufma@bidmc.harvard.edu
-
Contact:
- Patricia Tyler
- Phone Number: (617) 632-7727
- Email: ptyler@bidmc.harvard.edu
-
Principal Investigator:
- Peter Zimetbaum, MD
-
Boston, Massachusetts, United States, 02118
- Recruiting
- Boston Medical Center
-
Contact:
- Laura Gavrilles
- Phone Number: 617-638-8718
- Email: laura.gavrilles@bmc.org
-
Principal Investigator:
- Robert Helm
-
Boston, Massachusetts, United States, 02111
- Recruiting
- Tufts Medical Center
-
Contact:
- Nadia Bokhari
- Phone Number: 617-636-4276
- Email: Nadia.Bokhari@tuftsmedicine.org
-
Principal Investigator:
- Christopher Madias, MD
-
Burlington, Massachusetts, United States, 01805
- Recruiting
- Lahey Hospital & Medical Center
-
Contact:
- Jean Byrne
- Phone Number: 781-744-1901
- Email: jean.byrne@lahey.org
-
Principal Investigator:
- Matthew Reynolds
-
Worcester, Massachusetts, United States, 01655
- Recruiting
- Umass Chan Medical School
-
Contact:
- Shanna Spencer
- Phone Number: 508-856-3364
- Email: shanna.spencer@umassmed.edu
-
Contact:
- Aditi Singh
- Email: Aditi.Singh7@umassmed.edu
-
Principal Investigator:
- Michael Hyder, MD
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Health
-
Contact:
- Briita Wanhala
- Phone Number: 313-916-9575
- Email: bwanhal1@hfhs.org
-
Contact:
- Danielle Delmotte
- Phone Number: (313) 916-9575
- Email: ddelmot2@hfhs.org
-
Principal Investigator:
- Marc Lahiri
-
Grand Rapids, Michigan, United States, 49503
- Recruiting
- Corewell Health (Former Spectrum Health)
-
Contact:
- Lisa Van Loo
- Phone Number: 616-391-3327
- Email: lisa.vanloo@spectrumhealth.org
-
Contact:
- Meaghan Redmond
- Phone Number: (616) 391-2205
- Email: meaghan.redmond@spectrumhealth.org
-
Principal Investigator:
- Andre Gauri
-
Grand Rapids, Michigan, United States, 49503
- Recruiting
- Trinity Health Grand Rapids/Mercy Health
-
Contact:
- Lucas Vermaire
- Email: Lucas.vermaire@trinity-health.org
-
Principal Investigator:
- Muhammad Farooq, MD
-
Contact:
- Nicolina Evola
- Email: Nicolina.evola@trinity-health.org
-
Royal Oak, Michigan, United States, 48073
- Recruiting
- William Beaumont Hospital
-
Contact:
- Jon Teefey
- Phone Number: 248-898-5584
- Email: Jon.teefey@beaumont.org
-
Contact:
- Lauren Scribner
- Phone Number: (248) 898-5590
- Email: Lauren.scribner@beaumont.org
-
Principal Investigator:
- Nishaki Mehta
-
Ypsilanti, Michigan, United States, 48197
- Recruiting
- Trinity Health Michigan Heart - Ann Arbor
-
Contact:
- Autumn Howe
- Email: ahowe@michiganheart.com
-
Contact:
- Bozhena Stakh
- Email: bozhena_stakh@michiganheart.com
-
Principal Investigator:
- Mohammad-Ali Jazayeri
-
-
Minnesota
-
Duluth, Minnesota, United States, 55812
- Recruiting
- Essentia Health The Duluth Clinic
-
Contact:
- Allise Taran
- Email: allise.taran@essentiahealth.org
-
Principal Investigator:
- Siva Krothapalli, MD
-
Minneapolis, Minnesota, United States, 55455
- Not yet recruiting
- University of Minnesota
-
Contact:
- Julie Dicken
- Phone Number: 612-408-4316
- Email: dicke022@umn.edu
-
Contact:
- Maddy Chopp
- Phone Number: (612) 626-7041
- Email: Chopp015@umn.edu
-
Principal Investigator:
- Lin Yee Chen, MD
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Recruiting
- University Health Truman Medical Center
-
Contact:
- Mary Reed
- Phone Number: 816-404-1224
- Email: mary.reed@uhkc.org
-
Principal Investigator:
- Paramdeep Baweja, MD
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Contact:
- Janice Amsler
- Phone Number: 314-747-8542
- Email: jmamsler@wustl.edu
-
Principal Investigator:
- Thomas Maddox, MD
-
Contact:
- Sharon Heuerman
- Email: sheuerman@wustl.edu
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- Hackensack Meridian Health
-
Contact:
- Patricia Arakelian
- Phone Number: 551-996-5722
- Email: Patricia.Arakelian@hmhn.org
-
Principal Investigator:
- Tanya Glotzer
-
Piscataway, New Jersey, United States, 08854
- Recruiting
- Rutgers, The State University of New Jersey
-
Principal Investigator:
- Partho Sengupta
-
Contact:
- Glaucia Dos Santos-Vaccaro
- Phone Number: 732-235-6117
- Email: gd301@rwjms.rutgers.edu
-
Contact:
- Nivedita Rajiv
- Phone Number: (732) 418-8178
- Email: nr505@rwjms.rutgers.edu
-
Ridgewood, New Jersey, United States, 07450
- Recruiting
- The Valley Hospital, Inc.
-
Principal Investigator:
- Suneet Mittal
-
Contact:
- Kathleen Sayles
- Phone Number: 201-447-8453
- Email: ksayles@valleyhealth.com
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Recruiting
- University of New Mexico Health Sciences Center
-
Contact:
- Alexandra Yingling
- Phone Number: 505-272-1331
- Email: avyingling@salud.unm.edu
-
Principal Investigator:
- Abinash Achrekar, MD
-
Albuquerque, New Mexico, United States, 87106
- Recruiting
- Presbyterian Healthcare Services
-
Principal Investigator:
- Michael West, MD
-
Contact:
- Kristin Flores
- Phone Number: 505-563-2716
- Email: kflores15@phs.org
-
Contact:
- Avalon Abrums
- Phone Number: (505) 563-2716
- Email: aabrums3@phs.org
-
-
New York
-
Buffalo, New York, United States, 14214
- Recruiting
- University at Buffalo
-
Contact:
- Elizabeth Hejna
- Phone Number: 716-888-4736
- Email: ehejna@buffalo.edu
-
Contact:
- Courtney Bishop
- Phone Number: 716-888-4859
- Email: cabishop@buffalo.edu
-
Principal Investigator:
- Anne Curtis, MD
-
New York, New York, United States, 10016
- Recruiting
- NYU Langone Health
-
Principal Investigator:
- Joseph Germano, MD
-
Contact:
- Wendy Drewes
- Phone Number: 516-663-2929
- Email: wendy.drewes@nyulangone.org
-
Contact:
- Elizabeth Wolfrom
- Email: Elizabeth.Wolfrom@nyulangone.org
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Medical Center
-
Contact:
- Esteban Ceballos
- Phone Number: 917-797-5338
- Email: ec3539@cumc.columbia.edu
-
Principal Investigator:
- Angelo Biviano
-
New York, New York, United States, 10065
- Recruiting
- Weill Medical College of Cornell University
-
Contact:
- Dolores Reynolds
- Phone Number: 212-746-4617
- Email: Dtr2001@med.cornell.edu
-
Principal Investigator:
- Jim Cheung, MD
-
Contact:
- Penn Collins
- Phone Number: gpc4001@med.cornell.edu
-
Queens, New York, United States, 11355
- Recruiting
- NewYork Presbyterian - Queens
-
Principal Investigator:
- Joon Hyuk Kim
-
Contact:
- Bo Lwin
- Phone Number: 718-607-2944
- Email: bol9009@nyp.org
-
Valhalla, New York, United States, 10595
- Recruiting
- Westchester Medical Center
-
Contact:
- Fnu Namrata
- Phone Number: 914-493-5599
- Email: fnu.namrata@wmchealth.org
-
Principal Investigator:
- Jason Jacobson
-
Contact:
- Erida Castro-Rivas
- Email: Erida.Castro@wmchealth.org
-
White Plains, New York, United States, 10601
- Recruiting
- White Plains Hospital
-
Contact:
- Aileen Ferrick
- Phone Number: 914-849-2690
- Email: aferrick@wphospital.org
-
Principal Investigator:
- James Peacock
-
Contact:
- Uloma Ijomah
- Phone Number: (914) 849-2690
- Email: uijomah@wphospital.org
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- University of North Carolina
-
Contact:
- Meghan Allen
- Email: meghme@med.unc.edu
-
Principal Investigator:
- Anil Gehi, MD
-
Winston-Salem, North Carolina, United States, 27157
- Recruiting
- Wake Forest Baptist Health
-
Principal Investigator:
- Prashant Bhave
-
Contact:
- Keishia Rodriguez
- Email: kyrodrig@wakehealth.edu
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Recruiting
- University of Cincinnati College of Medicine
-
Contact:
- Rachel Mardis
- Phone Number: 513-558-3711
- Email: rachael.mardis@uc.edu
-
Contact:
- Carol Knochelmann
- Email: carol.knochelmann@uc.edu
-
Principal Investigator:
- Richard Becker
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- The Lindner Center for Research and Education at The Christ Hospital
-
Contact:
- Erica Jones
- Phone Number: 513-585-2298
- Email: Erica.Jones@thechristhospital.com
-
Contact:
- Rebecca Harper
- Phone Number: (513) 585-1777
- Email: RebeccaM.Harper@thechristhospital.com
-
Principal Investigator:
- Daniel Pelchovitz, MD
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University Medical Center
-
Principal Investigator:
- Salvatore Savona, MD
-
Contact:
- Adrianne Miller
- Phone Number: 614-688-8252
- Email: adrianne.miller3@osumc.edu
-
Wooster, Ohio, United States, 44691
- Recruiting
- Wooster Community Hospital
-
Contact:
- Erica Stahl
- Phone Number: 330-263-8359
- Email: estahl@wchosp.org
-
Principal Investigator:
- Cyril Ofori, MD
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- University of Oklahoma Health Sciences Center
-
Principal Investigator:
- Stavros Stavrakis, MD
-
Contact:
- Natalia Serrano
- Email: natalia-wellsserrano@ouhsc.edu
-
Contact:
- Aurora Vera
- Email: aurora-vera@ouhsc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- Recruiting
- Allegheny Singer Research Institute
-
Contact:
- Caitlin Phalunas
- Phone Number: 412-359-3747
- Email: caitlin.phalunas@ahn.org
-
Principal Investigator:
- Amit Thosani
-
Contact:
- Minesh Lathia
- Email: minesh.lathia@ahn.org
-
Wyomissing, Pennsylvania, United States, 19610
- Not yet recruiting
- Penn State Health Medical Group Berks Cardiology
-
Contact:
- Emese Futchko
- Phone Number: 610-685-8500
- Email: efutchko@pennstatehealth.psu.edu
-
Contact:
- Michelle Feltenberger
- Phone Number: (610) 685-8500
- Email: mfeltenberger@pennstatehealth.psu.edu
-
Principal Investigator:
- Ronald Polinsky, MD
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Not yet recruiting
- Rhode Island Hospital
-
Contact:
- Catherine Gordon
- Phone Number: 401-444-8598
- Email: cgordon@lifespan.org
-
Principal Investigator:
- Estelle Torbey, MD
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- Medical University of South Carolina
-
Contact:
- Jeffrey Winterfield
- Phone Number: 843-876-4760
- Email: winterfj@musc.edu
-
Principal Investigator:
- Rachel Kaplan
-
Columbia, South Carolina, United States, 29204
- Not yet recruiting
- MUSC Health Heart and Vascular
-
Contact:
- Jacqueline Sheriod-Scott
- Phone Number: 803-254-3278
- Email: sheriods@musc.edu
-
Principal Investigator:
- Venkateshwar Gottipaty, MD
-
-
Texas
-
Austin, Texas, United States, 78705
- Recruiting
- Texas Cardiac Arrhythmia Research Foundation
-
Contact:
- Deb Cardinal
- Phone Number: 512-431-4868
- Email: dscardinal@austinheartbeat.com
-
Principal Investigator:
- Amin Al Ahmad
-
Dallas, Texas, United States, 75390
- Recruiting
- University of Texas Southwestern Medical Center
-
Contact:
- Vukile Mlambo
- Phone Number: 214-648-3112
- Email: vukile.mlambo@utsouthwestern.edu
-
Principal Investigator:
- Mark Link, MD
-
Houston, Texas, United States, 77030
- Recruiting
- University of Texas Health Science Center at Houston
-
Contact:
- Anna Menezes
- Email: anna.m.menezes@uth.tmc.edu
-
Principal Investigator:
- Ijeoma Ekeruo, MD
-
Houston, Texas, United States, 77030
- Not yet recruiting
- Houston Methodist Hospital
-
Principal Investigator:
- Miguel Valderrabano, MD
-
Contact:
- Chinwe Ngumezi
- Phone Number: 346-238-0290
- Email: ccngumezi@houstonmethodist.org
-
Houston, Texas, United States, 77030
- Not yet recruiting
- Baylor College of Medicine
-
Principal Investigator:
- Mihail Chelu, MD
-
Contact:
- Stephen Harold
- Phone Number: 713-798-7227
- Email: harold@bcm.edu
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- Recruiting
- University of Virginia
-
Contact:
- Spencer Dennis
- Phone Number: 434-982-1058
- Email: gvj4ky@virginia.edu
-
Principal Investigator:
- Rohit Malhotra
-
Richmond, Virginia, United States, 23284
- Recruiting
- Virginia Commonwealth University
-
Principal Investigator:
- Kenneth Ellenbogen
-
Contact:
- Esoterica Berry
- Phone Number: 804-828-4700
- Email: esoterica.berry@vcuhealth.org
-
Contact:
- Mait Innes
- Phone Number: (804) 628-7455
- Email: david.innes@vcuhealth.org
-
-
Washington
-
Tacoma, Washington, United States, 98405
- Not yet recruiting
- St. Joseph Medical Center Tacoma
-
Contact:
- Jacqueline Lusk
- Email: Jacquelyn.Lusk@commonspirit.org
-
Principal Investigator:
- Gopi Dandamudi
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53706
- Recruiting
- University of Wisconsin
-
Contact:
- Karen Olson
- Email: kjolson@medicine.wisc.edu
-
Contact:
- Josh Hall
- Email: jjhall@medicine.wisc.edu
-
Principal Investigator:
- Jennifer Wright, MD
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Medical College of Wisconsin Froedtert Hospital
-
Contact:
- Shelley Schultz
- Phone Number: 414-955-6784
- Email: sschultz@mcw.edu
-
Contact:
- Debbi Hoff
- Email: dhoff@mcw.edu
-
Principal Investigator:
- Jason Rubenstein
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, 22-85 years of age.
- English speaking participants*
- Documented history of symptomatic or asymptomatic paroxysmal or persistent AF. The duration of AF must have been > 30 seconds as documented by an external monitor or present on 12-lead ECG.
- CHA2DS2-VASC score of 1-4 without prior stroke or Transient Ischemic Attack (TIA)**
- The participant is on a DOAC at the time of screening.
Willing and able to comply with the protocol, including:
- Possession of a smartwatch-compatible smartphone (iPhone that supports the latest shipping iOS) with a cellular service plan
- Be willing to wear the Apple watch at least 14 hours a day
- Expected to be within cellular service range at least 80% of the time
- Willing and able to discontinue DOAC
- The participant is willing and able to provide informed consent.
Exclusion Criteria:
- Valvular or permanent atrial fibrillation.
- Current treatment with warfarin and unwilling or unable to take a DOAC.
- The participant is a woman who is pregnant, nursing, or of child-bearing potential and is not on birth control.
- The participant is being treated with chronic aspirin, another anti-platelet agent, or chronic NSAIDS outside of current medical guidelines (e.g., primary stroke prevention in patients with atrial fibrillation, primary prevention of cardiovascular events, pain relief, fever, gout) and is unwilling or unable to discontinue use for the study duration.
- Existing cardiac rhythm device or indication for a permanent pacemaker, Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT) device or planned insertable cardiac monitor.
- Any documented single AF episode lasting ≥ 1 hour on screening external cardiac monitor of >=6 days duration.
- Mechanical prosthetic valve(s) or severe valve disease.
- Hypertrophic cardiomyopathy.
- Participant needs Direct Oral Anticoagulation (DOAC) for reasons other than preventing stroke or arterial embolism resulting from AF (i.e., preventing Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)) or needs permanent Oral Anticoagulant (OAC) (i.e., congenital heart defects, prosthetic heart valve).
- Participants deemed high risk for non-cardioembolic stroke (i.e., significant carotid artery disease defined as stenosis > 75%) based on the investigator's discretion.
- The participant is enrolled, has participated within the last 30 days, or is planning to participate in a concurrent drug and/or device study during the course of this clinical trial. Co-enrollment in concurrent trials is only allowed with documented pre-approval from the study manager; there is no concern that co-enrollment could confound the results of this trial.
- The participant has a tattoo, birthmark, or surgical scar over the dorsal wrist area on the ipsilateral side that the AFSW may be worn.
- The participant has a tremor on their ipsilateral side that the AFSW may be worn.
- Any concomitant condition that, in the investigator's opinion, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse).
- Known hypersensitivity or contraindication to direct oral anticoagulants.
- Documented prior stroke (ischemic or hemorrhagic) or transient ischemic attack.
- Reversible causes of AF (e.g., cardiac surgery, pulmonary embolism, untreated hyperthyroidism). AF ablation does not constitute reversible AF.
- > 5% burden premature atrial or ventricular depolarizations on any given calendar day on pre-enrollment cardiac monitoring.
- History of atrial flutter that has not been treated with ablation (participants in atrial flutter and have been ablated are eligible for enrollment).
- Stage 4 or 5 chronic kidney disease.
Conditions associated with an increased risk of bleeding:
- Major surgery in the previous month
- Planned surgery or intervention in the next three months.
- History of intracranial, intraocular, spinal, retroperitoneal, or atraumatic intra-articular bleeding
- Gastrointestinal hemorrhage within the past year unless the cause has been permanently eliminated (e.g., by surgery)
- Symptomatic or endoscopically documented gastroduodenal ulcer disease in the previous 30 days
- Hemorrhagic disorder or bleeding diathesis
- Need for anticoagulant treatment for disorders other than AF
- Required use of non-aspirin antiplatelet agents (i.e., Plavix) at time of enrollment
Uncontrolled hypertension (Systolic Blood Pressure (SBP) >180 mmHg and/or Diastolic Blood Pressure( DBP) >100 mmHg)
Spanish-only speakers may be included in the future at select sites where consent forms are appropriately translated.
- Congestive heart failure defined as: The presence of signs and symptoms of either right (elevated central venous pressure, hepatomegaly, dependent edema) or left ventricular failure (exertional dyspnea, cough, fatigue, orthopnea, paroxysmal nocturnal dyspnea, cardiac enlargement, rales, gallop rhythm, pulmonary venous congestion) or both, confirmed by non-invasive or invasive measurements demonstrating objective evidence of cardiac dysfunction and/or ejection fraction < 40%
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AFSW Guided DOAC
All participants randomized to the experimental arm will be provided with an AFSW that will be linked to the participants Apple watch and the secure REACT-AF app within the Eureka cloud.
The AFSW will intermittently and passively assess for rhythm irregularities consistent with AF and notify the wearer and coordinating center if a threshold AF event has occurred.
|
The AFSW will intermittently and passively assess for rhythm irregularities consistent with AF and notify the wearer and coordinating center if a threshold AF event has occurred.
Other Names:
|
Active Comparator: Continuous DOAC therapy
All participants randomized to the control arm will remain on previously prescribed FDA-approved DOAC regimen as indicated by current practice standards.
These participants will continuously take DOAC through the course of the study as prescribed by the participants primary physician unless otherwise contraindicated.
Participants in the control arm will also use the REACT-AF mobile app within the Eureka platform via Apple watch for study follow-up activities, but the participants will not receive an AFSW and any personally owned Apple Watch will not be loaded with the customized REACT-AF detection algorithm nor participant notification apps.
|
DOACs will be prescribed to patients according to the treating healthcare provider(s) according to labeling instructions.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess whether AFSW-guided, time-delimited DOAC therapy is non-inferior to continuous DOAC therapy for a composite endpoint that includes: (1) Ischemic stroke; (2) Systemic embolism; (3) All-cause mortality.
Time Frame: At 60 months
|
The primary objective (efficacy objective) of the REACT-AF trial is to assess whether AFSW-guided, time-delimited DOAC therapy is non-inferior to continuous DOAC therapy for a composite endpoint that includes: (1) Ischemic stroke; (2) Systemic embolism; and (3) All-cause mortality. Stroke is defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction; and classified as ischemic, hemorrhagic, or cause unknown based on CT or Magnetic Resonance (MR) scanning or autopsy. Systemic embolism is defined as an acute vascular occlusion of the extremities or any organ and must be documented by angiography, surgery, scintigraphy, or autopsy and require hospitalization. All-cause mortality will be defined as the underlying disease or injury that initiates the train of events resulting in death. |
At 60 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess whether AFSW-guided, time-delimited DOAC therapy significantly reduces major bleeding events compared to continuous DOAC therapy.
Time Frame: At 60 months
|
Oral anticoagulation carries a risk of major bleeding, including life-threatening hemorrhage, the intervention is expected to reduce the safety endpoint, major bleeding, by > 35%, and the study is powered for the superiority of the safety endpoint. Major bleeding will be defined as requiring hospitalization and by ≥1 of the following International Society on Thrombosis and Haemostasis (ISTH) criteria: (1) Bleeding associated with a reduction in hemoglobin level of at least 2.0 g/dL; (2) Bleeding leading to transfusion of at least two units of blood or packed cells; or (3) Symptomatic bleeding in a critical area or organ such as intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding. |
At 60 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Rod Passman, Northwestern University
- Principal Investigator: Dan Hanley, Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00354588
- 1U24HL165066-01 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on AFSW Guided DOAC
-
Takeshi MorimotoBayer Yakuhin, Ltd.Active, not recruitingNeoplasms | Venous Thrombosis | AnticoagulantsJapan
-
University Hospital, BrestUniversity Hospital of Saint-EtienneCompletedVenous ThromboembolismFrance
-
Haemonetics CorporationCompletedDOAC Eligible SubjectsUnited States
-
BayerCompletedStroke | Atrial Fibrillation | Prevention and ControlSpain
-
BayerCompletedStroke | Atrial Fibrillation | Prevention and ControlSpain
-
McMaster UniversitySt. Joseph's Healthcare Hamilton; Hamilton Health Sciences CorporationUnknownAtrial FibrillationCanada
-
Boehringer IngelheimCompleted
-
Fondation Ophtalmologique Adolphe de RothschildCompletedPer-procedural Concentrations of Oral AnticoagulantsFrance
-
Ottawa Hospital Research InstituteRecruitingGastroIntestinal Bleeding | Anticoagulant-induced BleedingCanada
-
Cliniques universitaires Saint-Luc- Université...CompletedHemorrhage | Embolism and ThrombosisBelgium